Abstract

Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful. We used a novel strategy to combine properties of 2 well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. Bearing in mind that sulfonamide moiety and pyrazole ring is important for the proapoptotic activity of Celecoxib, we synthesized a selenium derivative, Selenocoxib-1, by modifying Celecoxib at position 3 of the pyrazole ring. The PAIII cells derived from a metastatic prostate tumor that arose spontaneously in a Lobund-Wistar (LW) rat were used to examine the efficacy of Selenocoxib-1 in vitro. In addition, human metastatic prostate cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. The IC50 in PAIII and PC-3M cells for Selenocoxib-1 was about 5 μM, while for Celecoxib it was more than 20 μM. Selenocoxib-1 induced apoptosis in a dose-dependent manner in the PAIII cells. COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 μM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1. Following treatment with Selenocoxib-1, PAIII cells resulted in dose-dependent decrease in HIF-1α, p-AKT and Bcl-2 levels. A reduction in weights was observed in subcutaneous tumors produced by PAIII cells pretreated with Selenocoxib-1 as compared to Celecoxib in LW rats. Further, following 1 week Selenocoxib-1 treatment of PAIII tumors resulted in significant reduction of tumor weights. This study demonstrates that Selenocoxib-1 is more effective against prostate cancer than Celecoxib.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalInternational Journal of Cancer
Volume127
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Celecoxib
Prostate
Adenocarcinoma
Prostatic Neoplasms
Wistar Rats
selenocoxib-1
Selenium Compounds
Neoplasms
Cyclooxygenase 2 Inhibitors
Sulfonamides
Standard of Care
Selenium
Tumor Burden
Inhibitory Concentration 50
Weight Loss
Down-Regulation
Hormones
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{ec2c8117ba5b41bc84bee50e4593c83d,
title = "Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells",
abstract = "Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful. We used a novel strategy to combine properties of 2 well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. Bearing in mind that sulfonamide moiety and pyrazole ring is important for the proapoptotic activity of Celecoxib, we synthesized a selenium derivative, Selenocoxib-1, by modifying Celecoxib at position 3 of the pyrazole ring. The PAIII cells derived from a metastatic prostate tumor that arose spontaneously in a Lobund-Wistar (LW) rat were used to examine the efficacy of Selenocoxib-1 in vitro. In addition, human metastatic prostate cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. The IC50 in PAIII and PC-3M cells for Selenocoxib-1 was about 5 μM, while for Celecoxib it was more than 20 μM. Selenocoxib-1 induced apoptosis in a dose-dependent manner in the PAIII cells. COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 μM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1. Following treatment with Selenocoxib-1, PAIII cells resulted in dose-dependent decrease in HIF-1α, p-AKT and Bcl-2 levels. A reduction in weights was observed in subcutaneous tumors produced by PAIII cells pretreated with Selenocoxib-1 as compared to Celecoxib in LW rats. Further, following 1 week Selenocoxib-1 treatment of PAIII tumors resulted in significant reduction of tumor weights. This study demonstrates that Selenocoxib-1 is more effective against prostate cancer than Celecoxib.",
author = "Dhimant Desai and Indu Sinha and Kevin Null and William Wolter and Suckow, {Mark A.} and Tonya King and Shantu Amin and Raghu Sinha",
year = "2010",
month = "7",
day = "1",
doi = "10.1002/ijc.25033",
language = "English (US)",
volume = "127",
pages = "230--238",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells. / Desai, Dhimant; Sinha, Indu; Null, Kevin; Wolter, William; Suckow, Mark A.; King, Tonya; Amin, Shantu; Sinha, Raghu.

In: International Journal of Cancer, Vol. 127, No. 1, 01.07.2010, p. 230-238.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells

AU - Desai, Dhimant

AU - Sinha, Indu

AU - Null, Kevin

AU - Wolter, William

AU - Suckow, Mark A.

AU - King, Tonya

AU - Amin, Shantu

AU - Sinha, Raghu

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful. We used a novel strategy to combine properties of 2 well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. Bearing in mind that sulfonamide moiety and pyrazole ring is important for the proapoptotic activity of Celecoxib, we synthesized a selenium derivative, Selenocoxib-1, by modifying Celecoxib at position 3 of the pyrazole ring. The PAIII cells derived from a metastatic prostate tumor that arose spontaneously in a Lobund-Wistar (LW) rat were used to examine the efficacy of Selenocoxib-1 in vitro. In addition, human metastatic prostate cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. The IC50 in PAIII and PC-3M cells for Selenocoxib-1 was about 5 μM, while for Celecoxib it was more than 20 μM. Selenocoxib-1 induced apoptosis in a dose-dependent manner in the PAIII cells. COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 μM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1. Following treatment with Selenocoxib-1, PAIII cells resulted in dose-dependent decrease in HIF-1α, p-AKT and Bcl-2 levels. A reduction in weights was observed in subcutaneous tumors produced by PAIII cells pretreated with Selenocoxib-1 as compared to Celecoxib in LW rats. Further, following 1 week Selenocoxib-1 treatment of PAIII tumors resulted in significant reduction of tumor weights. This study demonstrates that Selenocoxib-1 is more effective against prostate cancer than Celecoxib.

AB - Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful. We used a novel strategy to combine properties of 2 well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. Bearing in mind that sulfonamide moiety and pyrazole ring is important for the proapoptotic activity of Celecoxib, we synthesized a selenium derivative, Selenocoxib-1, by modifying Celecoxib at position 3 of the pyrazole ring. The PAIII cells derived from a metastatic prostate tumor that arose spontaneously in a Lobund-Wistar (LW) rat were used to examine the efficacy of Selenocoxib-1 in vitro. In addition, human metastatic prostate cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. The IC50 in PAIII and PC-3M cells for Selenocoxib-1 was about 5 μM, while for Celecoxib it was more than 20 μM. Selenocoxib-1 induced apoptosis in a dose-dependent manner in the PAIII cells. COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 μM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1. Following treatment with Selenocoxib-1, PAIII cells resulted in dose-dependent decrease in HIF-1α, p-AKT and Bcl-2 levels. A reduction in weights was observed in subcutaneous tumors produced by PAIII cells pretreated with Selenocoxib-1 as compared to Celecoxib in LW rats. Further, following 1 week Selenocoxib-1 treatment of PAIII tumors resulted in significant reduction of tumor weights. This study demonstrates that Selenocoxib-1 is more effective against prostate cancer than Celecoxib.

UR - http://www.scopus.com/inward/record.url?scp=77953441260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953441260&partnerID=8YFLogxK

U2 - 10.1002/ijc.25033

DO - 10.1002/ijc.25033

M3 - Article

C2 - 19918950

AN - SCOPUS:77953441260

VL - 127

SP - 230

EP - 238

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -